“Lotus clear plague family, earn money until hand cramps.”
The two top authoritative media breaking news from Caixin.com and Titanium Media have once again brought this “anti-novelty crown” miracle drug to light.
The author of the controversial paper is Jia Zhenhua, who is married to Wu Rui, the daughter of Ealing Pharmaceutical Chairman Wu Yiling, the sole manufacturer of Lotus Clear Fever capsules/granules.
The efficacy of Lotus Clear Fever has once again become the focus of public opinion.
While many people have lost their fortunes in the epidemic, Wu Yiling’s wealth has soared nearly twofold in the first five months of last year.
His stock assets are as high as 12 billion yuan at the latest closing price.
Lotus Clear Distemper capsules were endorsed by a number of heavyweight experts in the new crown treatment, and the stock price soared nearly 200% at one point during the year under market pursuit.
This may not be rational growth, but is a good time for major shareholders to realize their wealth.
The Wu family absolutely controls Ealing Pharmaceuticals, with Wu Ealing and his son Wu Xiangjun and daughter Wu Rui holding a combined 54.21% (according to the 2019 annual report).
The official endorsement did not eliminate the controversy about “Lotus Clear Distemper Capsules”.
The status of “proprietary Chinese medicine”, the fact that it is only used for the treatment of mild diseases and the ambiguous attitude of countries other than China towards Lotus Clear Distemper Capsules have invariably given rise to the controversy.
Some people believe that the new crown can be self-healing, and thus question whether the effectiveness of Lotus Clear Distemper Capsules is exaggerated.
The “Chinese medicine controversy” has always been a radical proposition that divides the Internet world into two factions.
The capital frenzy of Ealing Pharmaceuticals began on April 12, 2020.
On that day, the instructions for Lianhua Qingfei capsule (granules) were approved by the Drug Administration, adding “in the routine treatment of novel coronavirus pneumonia, it can be used for fever, cough and weakness caused by light, common type.”
This was interpreted by some as “the world’s first drug to treat mild cases of novel coronavirus pneumonia”. The company’s share price then rose.
Previously in several versions of the “new coronavirus pneumonia diagnosis and treatment program”, Lianhua Qingfei capsule were included.
Last year, in a press conference held by the State Council Information Office, Lianhua Qingfei, Golden Flower QingSense Granules, Blood Bijou Injection, Clear Lung Detoxification Soup, Dampness and Poisoning Formula, and Xuanlung and Poisoning Formula were called the “Three Medicines Tripartite” with obvious efficacy.
In the health package for overseas students, besides masks and disinfectant tissues, two boxes of Lianhua Qingpu capsules are also the only medicines.
What pushed Ealing’s fortune to the highest point was the three public and clear endorsements from academician Zhong.
The first time was when the world-renowned pharmacology journal Pharmacology Research published an article titled “Lianhua Qingfei has antiviral and anti-inflammatory effects on a new coronavirus”.
The authors of the paper included academician Zhong Nanshan, director of the State Key Laboratory of Respiratory Diseases of Guangzhou Medical University, and researcher Yang Zifeng.
For the second time, Tencent Medical Dictionary invited Academician Zhong Nanshan to answer questions related to the new coronavirus pneumonia epidemic.
In his review of several anti-epidemic drugs, Academician Zhong said that Lianhua Qingfei was effective in reducing fever, reducing respiratory cough symptoms and speeding up recovery. For the rate of viral transitions compared to the control group, it has a tendency to shorten. We believe that for the mild and common type, Lianhua Qingfei is proven to be effective.
The good news intensively boosted, Ealing Pharmaceuticals stock price rose continuously. once climbed to the highest point of 41.69 yuan on April 17, the market value exceeded 50 billion yuan.
For the third time, Academician Zhong said during a video link with overseas students.
After conducting experiments, I have the strength and evidence to say that Lianhua Qingbi really works.
While the domestic community is crowning Lianhua Qingfei capsules, there are different voices abroad.
In Canada, an international student posted on a social media platform that he had received Lianhua Qingfei capsules. This came to the attention of Health Canada, whose spokesperson said, “It is illegal in Canada to sell unauthorized health products or make false or misleading claims to treat or cure COVID-19.”
Dr. Peter Lin, a native Canadian academic and CBC medical columnist, stated.
“A product that can treat the symptoms of COVID-19 does not mean that it can treat the coronavirus itself. Treating the symptoms of a disease should not be confused with treating the disease.”
In Sweden, there was a lot of controversy when the Swedish media reported that “the Swedish customs laboratory tested the Chinese promoted anti-new coronavirus herb Lianhua Qingfei, claiming that its ingredient was “only menthol” (a major ingredient used in the widespread production of sugar).
In North America, it was reported that a North American country had refused to allow the capsules to enter the country because “they are rich in aristolochic acid, a chemical that is carcinogenic and nephrotoxic”.
There was no clearer data on the efficacy of Lianhua Qingfei capsules until the middle and late stages of the fight against the new crown.
Academician Zhong Nanshan and Academician Li Lanjuan co-directed a joint study of Lianhua Qingfei RCT (Randomized Controlled Trial) in 23 hospitals in 9 provinces and cities across China, which included a total of 284 patients with neo-crown pneumonia.
They gave the results of the study, “The disappearance rate of major clinical symptoms and the duration of clinical symptoms were better in the treatment group than in the control group, and the improvement of lung imaging reached 83.8%, compared with 64.1% in the control group. The clinical cure rate was 78.9% compared with 66.2% in the control group, and the treatment group was significantly better than the control group. In terms of mild to severe disease, the treatment group was 50% lower than the control group. And in recently completed in vitro experiments, it has also been demonstrated that Lianhua Qingfei has an inhibitory effect on neo-crown virus in vitro.”
This set of controlled trials also generated some discussion at the time because of the self-healing nature of Neocon mild disease and the fact that only in vitro trials had been completed.
Another concern is that back in 2019, academician Wu Yiling funded the establishment of the “Nanshan-Yiling Lung Complex Joint Research Center” with academician Zhong Nanshan at Guangzhou Medical University.
At the launch ceremony, academician Zhong “fully recognized academician Wu Yiling and gave high praise.” Academician Wu Yiling delivered a speech to “sincerely thank Academician Zhong for his continuous concern and support for the development of Chinese medicine.”
This is the beginning of the century, while owning hospitals, pharmaceutical companies and construction companies, Wu Yiling academician’s business talent than medical skills.
The SARS virus arrived suddenly in 2003. In response to the SARS virus, the soon established Yiling Pharmaceutical made the Chinese patent medicine Lianhua Qingfei capsule/granule based on the addition and subtraction changes of Ma Heng Shi Gan Tang from the Treatise on Typhoid Fever and Yin Qiao San from the Article of Warming Diseases.
Unfortunately, the Chinese medicine Lian Hua Qing Fei was crushed by a generation of miracle medicine Ban Lan Gen and did not gain wide recognition.
The birth of the miracle medicine Banlangen is also magical. No one could know exactly what kind of diseases Banlangen could cure, and every time there was an epidemic, every child would be asked to drink a bowl of “sweet” Banlangen by adults.
In 2008, the then president of the Chinese Medical Association, Zhong Nanshan’s team announced that “the mysterious mechanism of antiviral of Banlangen has been preliminarily detected”; later, when the Ebola virus broke out, China donated more than 100,000 packs of the antiviral drug Banlangen to Africa with love, and Banlangen went global.
In 2013, the H7N9 avian influenza outbreak, the characteristics of the virus have not been studied clearly, many places claim that “Pan Lan Gen can prevent H7N9 avian influenza”.
However, Lianhua Qingfei capsule later staged a comeback script, 2005-2019, Lianhua Qingfei capsule cumulative 18 times by the relevant departments in the treatment of influenza and other respiratory diseases treatment program.
During the 2009 influenza A (H1N1) pandemic, Lianhua Qingfei was used in 60 million boxes nationwide in 3 months.
By 2020, Lotus Clear Distemper capsule finally ascended to the altar and became the top stream of Chinese patent medicine generation.
Turning to the financial report of Ealing Pharmaceuticals, the revenue in 2019 was 5.825 billion yuan, the sales expense was 2.227 billion yuan, accounting for 38.23% of the total operating cost, and the R&D expense was 391 million yuan.
This has the common characteristics of proprietary Chinese medicine companies – high selling expenses and mediocre R&D investment.
Pharmaceutical companies’ sales expenses have always been unexplainable, and if they specialize in prescription drugs for hospitals, offering kickbacks to hospitals and doctors, the chaos of selling with gold is frequently exposed, and this part of the cost will be hidden into the sales expenses.
Sales expenses include a variety of items such as market development and academic promotion expenses, advertising, travel expenses, conference fees and business hospitality expenses to facilitate kickbacks away from the accounts.
Chinese patent medicines often have the characteristics of treating a wide range of diseases and departments, and thus become a “panacea” for complementary medicine, especially suitable for such gray areas.
In the case of over-the-counter drugs (OTC drugs for short) placed in pharmacies, advertising bombardment is the golden rule to pull the market.
The advertising slogan should be “clear symptoms, vague population”, and the target group can be expanded as much as possible.
If you don’t believe in it, you can taste: “Happiness comes from life, health comes from gum”, “Kyoto Niancian, regulating heart and lowering fire, exhaling vitality” ……
In 2017, CK CMH research published a survey, there are 11 OTC star single products with a retail terminal sales scale of over 1 billion, all of which are proprietary Chinese medicines.
Among them, Dong Ah Gao has become the largest single product in OTC scale, with an advertising cost of 513 million yuan.
Lianhua Qingfei has been listed for many years, with many scholars endorsing it. When the capital stirred in it, something indefinable, suddenly become more complex.
And now Jia Zhenhua as the son-in-law of the boss of Ealing Pharmaceuticals, when the endorsement for his old husband, although it is said to raise the sage not to avoid relatives, but the scientific nature of the paper, objectivity and authority and how much more water out?
I hope that the big wave can remove the sand, to remove the false and keep the truth.
The ethical justice has its own determination.
Recent Comments